# EDGAR Filing Document

**Accession Number:** 0001469443
**File Stem:** 0001209191-23-002168
**Filing Date:** 2023-1
**Character Count:** 10296
**Document Hash:** 093d14f105d748e01c2bbf216599c9c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-002168.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0001209191-23-002168

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230103

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Schaefer Thomas J.
- **CENTRAL INDEX KEY:** 0001960808

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37383
- **FILM NUMBER:** 23513374

**MAIL ADDRESS:**
- **STREET 1:** 202 COUSTEAU PLACE STE 105
- **CITY:** DAVIS
- **STATE:** CA
- **ZIP:** 95618
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arcadia Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001469443
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE PRODUCTION - CROPS [0100]
- **IRS NUMBER:** 810571538
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 202 COUSTEAU PLACE
- **STREET 2:** SUITE 105
- **CITY:** DAVIS
- **STATE:** X1
- **ZIP:** 95618
- **BUSINESS PHONE:** 530-756-7077

**MAIL ADDRESS:**
- **STREET 1:** 202 COUSTEAU PLACE
- **STREET 2:** SUITE 105
- **CITY:** DAVIS
- **STATE:** CA
- **ZIP:** 95618

## Ex-24

```

POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints each of Pamela Haley and
Solaeta Chan, signing singly, the undersigned's true and lawful attorney-in-fact
to:

(i)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of
Arcadia Biosciences, Inc. (the "Company"), Forms 3, 4 and 5  (including
amendments thereto), and for the
purpose of filing such Forms, to execute and deliver any documents necessary to
the Securities and
Exchange Commission ("SEC") for the purpose of obtaining EDGAR codes, all in
accordance with Section
16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and the rules and
regulations promulgated thereunder;

(ii)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to
complete and execute any such Forms 3, 4 or 5 and timely file such form
(including amendments thereto)
with the SEC and any stock exchange or similar authority; and

(iii)	take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest of, or legally
required by the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to
this Power of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-
in-fact may approve in such attorney-in-fact's discretion.

       The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and
every act and thing whatsoever requisite, necessary or proper to be done in the
exercise of any of the rights and
powers herein granted, as fully to all intents and purposes as the undersigned
might or could do if personally present,
with full power of substitution and revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney
and the rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming nor
is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.

       The undersigned agrees that such attorney-in-fact may rely entirely on
information furnished orally or in
writing by the undersigned to such attorney-in-fact.  The undersigned also
agrees to indemnify and hold harmless
the Company and such attorney-in-fact against any losses, claims, damages or
liabilities (or actions in these
respects) that arise out of or are based on any untrue statement or omission of
necessary facts in the information
provided by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing
Forms 3, 4 or 5 (including amendments thereto) and agrees to reimburse the
Company and such attorney-in-fact for
any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss,
claim, damage, liability or action.

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to
file Forms 3, 4 or 5 with respect to the undersigned's holdings of and
transactions in securities issued by the
Company, unless earlier (a) revoked by the undersigned in a signed writing
delivered to the foregoing attorney-in-
fact or (b) superseded by a new power of attorney regarding the purposes
outlined in the first paragraph hereof as of
a later date.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 6th day of December, 2022.

	Signature:				/s/ Thomas J. Schaefer

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Schaefer Thomas J.<br><sub>(Last) (First) (Middle)</sub><br>C/O ARCADIA BIOSCIENCES<br>202 COUSTEAU PLACE, SUITE 105<br><sub>(Street)</sub><br>DAVIS, CA 95618<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Arcadia Biosciences, Inc. [ RKDA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-03 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Financial Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 2100 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2030-07-27 | Common Stock | 8000 | $3.67 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2031-01-21 | Common Stock | 4000 | $3.05 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2031-10-01 | Common Stock | 20000 | $2.09 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2032-04-11 | Common Stock | 23000 | $1.27 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2032-04-11 | Common Stock | 31000 | $1.27 | D |  |
| Stock Option (Right to Buy) | <sup>(6)</sup> | 2032-08-16 | Common Stock | 23000 | $0.94 | D |  |

---

### Footnotes:

(1) The options were granted on 7/27/2020 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.

(2) The options were granted on 1/21/2021 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.

(3) The options will vest monthly in equal installments over a period of four years from the date of the grant, 10/1/2021, subject to the Participant's continued service.

(4) The options will vest annually in equal installments over a period of two years from the date of the grant, 4/11/2022, subject to the Participant's continued service.

(5) The options were granted on 4/11/2022 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.

(6) The options will vest annually in equal installments over a period of three years from the date of the grant, 8/16/2022, subject to the Participant's continued service.

**Signature:** Thomas Schaefer, by Attorney-in-fact, Solaeta Chan  
**Date:** 2023-01-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**